IDiyas

For the Inventor, By the Inventor

Koebenhavn N, Denmark

Carsten Behrens

USPTO Granted Patents = 20 

 

Average Co-Inventor Count = 5.5

ph-index = 7

Forward Citations = 193(Granted Patents)


Location History:

  • København, DK (2003)
  • Kobenhavn, DK (2005)
  • Kobenhavn N, DK (2011)
  • København N, DK (2014 - 2015)
  • Koebenhavn N, DK (2014 - 2017)
  • Copenhagen, DK (2003 - 2021)
  • Koebenhavn, DK (2019 - 2023)

Company Filing History:

goldMedal10 out of 1,777 
 
Novo Nordisk A/s
 patents
silverMedal6 out of 88 
 
Novo Nordisk Healthcare Ag
 patents
bronzeMedal2 out of 77 
 
University of Copenhagen
 patents
4. 2 out of 228 
 
Danmarks Tekniske Universitet
 patents
5. 1 out of 5 
 
Noro Nordisk A/s
 patents
6. 1 out of 6 
 
Novo Nordick A/s
 patents
where one patent can have more than one assignee

Years Active: 2003-2025

Loading Chart...
Loading Chart...
20 patents (USPTO):Explore Patents
1. 12227528 - Glucose-sensitive albumin-binding derivatives (2025-02-18),
2. 11767332 - Glucose-sensitive albumin-binding derivatives (2023-09-26),
3. 11186595 - Glucose-sensitive albumin-binding derivatives (2021-11-30),
4. 10889845 - Production of N-glycoproteins for enzyme assisted glycomodification (2021-01-12),
5. 10858671 - N-glycosylation (2020-12-08),
6. 10179905 - Factor VII conjugates (2019-01-15),
7. 9695226 - Growth hormones with prolonged in-vivo efficacy (2017-07-04),
8. 9370583 - Coagulation factor VII polypeptides (2016-06-21),
9. 9234192 - Conjugated proteins (2016-01-12),
10. 9018166 - Conjugated FVIII variants (2015-04-28),
11. 8865868 - Conjugated proteins with prolonged in vivo efficacy (2014-10-21),
12. 8779109 - Growth hormones with prolonged in-vivo efficacy (2014-07-15),
13. 8053410 - Pegylated factor VII glycoforms (2011-11-08),
14. 6953812 - Glucagon antagonists/inverse agonists (2005-10-11),
15. 6927214 - Non-peptide GLP-1 agonists (2005-08-09),

Title: Carsten Behrens: Pioneering Innovations in Glucose-Sensitive Derivatives

Introduction: Carsten Behrens, based in Koebenhavn N, Denmark, is a distinguished inventor recognized for his remarkable contributions to the field of biochemistry with a notable portfolio of 20 patents. His innovations primarily focus on glucose-sensitive compounds, which hold significant potential in medical applications.

Latest Patents: Among his latest contributions to the scientific community is the invention relating to glucose-sensitive albumin-binding diboron conjugates. This invention involves novel diboron compounds, specifically diboronate or diboroxole compounds, that serve as intermediate compounds for the synthesis of diboron conjugates. This advancement is poised to influence therapeutic approaches in glucose monitoring and regulation.

Career Highlights: Carsten has had a significant career with key roles at reputable companies such as Novo Nordisk A/S and Novo Nordisk Healthcare AG. His work in these organizations has furthered research in diabetes care and treatment options, solidifying his reputation as a leading figure in the pharmaceutical industry.

Collaborations: Throughout his career, Carsten has collaborated with esteemed professionals, including Peter Madsen and Jesper F Lau. These collaborations have enhanced his research and contributed to the successful development of innovative patent offerings.

Conclusion: Carsten Behrens exemplifies the spirit of innovation that drives advancements in healthcare. His 20 patents, particularly in glucose-sensitive albumin-binding derivatives, reflect his commitment to enhancing therapeutic methodologies. As the landscape of biochemistry continues to evolve, Carsten's contributions stand as a testament to the profound impact of dedicated inventors in shaping future medical solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…